Latent Tuberculosis Infection (LTBI) Testing Market by Test Type and Application- Global Industry Analysis & Forecast to 2027
Published On : March 2021 Pages : 169 Category: Pharma & Healthcare Report Code : HC0316590
Latent Tuberculosis Infection (LTBI) Testing Market By Test Type (Tuberculin Skin Test (TST) and Interferon Gamma Released Assay (IGRA)); Application (Hospitals, Diagnostic Centers, Laboratories, and Others)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Latent Tuberculosis Infection (LTBI) Testing Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Latent Tuberculosis Infection (LTBI) Testing is made if a person has a positive TB test result and a medical evaluation does not indicate TB disease. The decision about treatment for latent TB infection will be based on a person’s chances of developing TB disease by considering their risk factors.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Latent Tuberculosis Infection (LTBI) Testing Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- QIAGEN
- BioMeriux S.A.
- F. Hoffmann La-Roche Ltd.
- BD
- ARKRAY, Inc.
- Abbott
- Serum Institute of India Pvt. Ltd
- Oxford Immunotec Ltd
- Lionex GmbH
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Latent Tuberculosis Infection (LTBI) Testing Market , By Type, Estimates and Forecast, 2017-2027 ($Million)
o Tuberculin Skin Test (TST)
o Interferon Gamma Released Assay (IGRA)
· Latent Tuberculosis Infection (LTBI) Testing Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals
o Diagnostic Centers
o Laboratories
o Others
· Latent Tuberculosis Infection (LTBI) Testing Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o QIAGEN
o BioMeriux S.A.
o F. Hoffmann La-Roche Ltd.
o BD
o ARKRAY, Inc.
o Abbott
o Serum Institute of India Pvt. Ltd
o Oxford Immunotec Ltd
o Lionex GmbH
· Latent Tuberculosis Infection (LTBI) Testing Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Latent Tuberculosis Infection (LTBI) Testing Market , By Country
o U.S. Latent Tuberculosis Infection (LTBI) Testing Market
o Canada Latent Tuberculosis Infection (LTBI) Testing Market
o Mexico Latent Tuberculosis Infection (LTBI) Testing Market
o Europe
§ Europe Latent Tuberculosis Infection (LTBI) Testing Market , By Country
o UK Latent Tuberculosis Infection (LTBI) Testing Market
o Germany Latent Tuberculosis Infection (LTBI) Testing Market
o France Latent Tuberculosis Infection (LTBI) Testing Market
o Russia Latent Tuberculosis Infection (LTBI) Testing Market
o Italy Latent Tuberculosis Infection (LTBI) Testing Market
o Rest of Europe Latent Tuberculosis Infection (LTBI) Testing Market
o Asia-Pacific
§ Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market , By Country
o China Latent Tuberculosis Infection (LTBI) Testing Market
o Japan Latent Tuberculosis Infection (LTBI) Testing Market
o South Korea Latent Tuberculosis Infection (LTBI) Testing Market
o India Latent Tuberculosis Infection (LTBI) Testing Market
o Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Market
o Rest of Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market
o South America
§ South America Latent Tuberculosis Infection (LTBI) Testing Market
o Brazil Latent Tuberculosis Infection (LTBI) Testing Market
o Argentina Latent Tuberculosis Infection (LTBI) Testing Market
o Columbia Latent Tuberculosis Infection (LTBI) Testing Market
o Rest of South America Latent Tuberculosis Infection (LTBI) Testing Market
o Middle East and Africa
§ Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Market
o Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Market
o UAE Latent Tuberculosis Infection (LTBI) Testing Market
o Egypt Latent Tuberculosis Infection (LTBI) Testing Market
o Nigeria Latent Tuberculosis Infection (LTBI) Testing Market
o South Africa Latent Tuberculosis Infection (LTBI) Testing Market
o Turkey Latent Tuberculosis Infection (LTBI) Testing Market
o Rest of MEA Latent Tuberculosis Infection (LTBI) Testing Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Latent Tuberculosis Infection (LTBI) Testing Market, By Type
5.1. Introduction
5.2. Global Latent Tuberculosis Infection (LTBI) Testing Revenue and Market Share by Type (2017-2021)
5.2.1. Global Latent Tuberculosis Infection (LTBI) Testing Revenue and Revenue Share by Type (2017-2021)
5.3. Tuberculin Skin Test (TST)
5.3.1. Global Tuberculin Skin Test (TST) Revenue and Growth Rate (2017-2021)
5.4. Interferon Gamma Released Assay (IGRA)
5.4.1. Global Interferon Gamma Released Assay (IGRA) Revenue and Growth Rate (2017-2021)
6. Latent Tuberculosis Infection (LTBI) Testing Market, By Applications
6.1. Introduction
6.2. Global Latent Tuberculosis Infection (LTBI) Testing Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Latent Tuberculosis Infection (LTBI) Testing Revenue and Revenue Share by Applications (2017-2021)
6.3. Hospitals
6.3.1. Global Hospitals Revenue and Growth Rate (2017-2021)
6.4. Diagnostic Centers
6.4.1. Global Diagnostic Centers Revenue and Growth Rate (2017-2021)
6.5. Laboratories
6.5.1. Global Laboratories Revenue and Growth Rate (2017-2021)
6.6. Others
6.6.1. Global Others Revenue and Growth Rate (2017-2021)
7. Latent Tuberculosis Infection (LTBI) Testing Market, By Region
7.1. Introduction
7.2. Global Latent Tuberculosis Infection (LTBI) Testing Revenue and Market Share by Regions
7.2.1. Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Regions (2017-2021)
7.3. North America Latent Tuberculosis Infection (LTBI) Testing by Countries
7.3.1. North America Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2021)
7.3.2. North America Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Latent Tuberculosis Infection (LTBI) Testing by Countries
7.4.1. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2021)
7.4.2. Europe Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing by Countries
7.5.1. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Latent Tuberculosis Infection (LTBI) Testing by Countries
7.6.1. South America Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2021)
7.6.2. South America Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing by Countries
7.7.1. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. QIAGEN
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. BioMeriux S.A.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. F. Hoffmann La-Roche Ltd.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. BD
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. ARKRAY, Inc.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Abbott
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Serum Institute of India Pvt. Ltd
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Oxford Immunotec Ltd
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Lionex GmbH
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
9. Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.1. Global Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Latent Tuberculosis Infection (LTBI) Testing Market Forecast by Regions (2022-2027)
9.2.1. North America Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.1.1. United States Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.1.2. Canada Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.1.3. Mexico Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.2. Europe Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.2.1. Germany Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.2.2. France Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.2.3. UK Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.2.4. Russia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.2.5. Italy Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.3. Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.3.1. China Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.3.2. Japan Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.3.3. Korea Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.3.4. India Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.4. South America Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.4.1. Brazil Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.4.2. Argentina Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.4.3. Columbia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.4.4. Rest of South America Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5. Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5.3. Egypt Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5.4. Nigeria Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5.5. South Africa Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5.6. Turkey Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2022-2027)
9.3. Latent Tuberculosis Infection (LTBI) Testing Market Forecast by Type (2022-2027)
9.3.1. Latent Tuberculosis Infection (LTBI) Testing Forecast by Type (2022-2027)
9.3.2. Latent Tuberculosis Infection (LTBI) Testing Market Share Forecast by Type (2022-2027)
9.4. Latent Tuberculosis Infection (LTBI) Testing Market Forecast by Applications (2022-2027)
9.4.1. Latent Tuberculosis Infection (LTBI) Testing Forecast by Applications (2022-2027)
9.4.2. Latent Tuberculosis Infection (LTBI) Testing Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Latent Tuberculosis Infection (LTBI) Testing Revenue and Revenue Share by Type (2017-2019)
Figure Global Tuberculin Skin Test (TST) Revenue and Growth Rate (2017-2019)
Figure Global Interferon Gamma Released Assay (IGRA) Revenue and Growth Rate (2017-2019)
Table Global Latent Tuberculosis Infection (LTBI) Testing Revenue and Revenue Share by Applications (2017-2019)
Figure Global Hospitals Revenue and Growth Rate (2017-2019)
Figure Global Diagnostic Centers Revenue and Growth Rate (2017-2019)
Figure Global Laboratories Revenue and Growth Rate (2017-2019)
Figure Global Others Revenue and Growth Rate (2017-2019)
Table Global Latent Tuberculosis Infection (LTBI) Testing Revenue by Regions (2017-2019)
Figure North America Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure North America Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2019)
Figure North America Latent Tuberculosis Infection (LTBI) Testing by Countries (2017-2019)
Figure North America Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2019)
Figure United States Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure United States Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Canada Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Mexico Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Europe Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2019)
Figure Europe Latent Tuberculosis Infection (LTBI) Testing by Countries (2017-2019)
Figure Europe Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2019)
Figure Germany Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Germany Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure France Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure UK Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Russia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Italy Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Rest of Europe Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing by Countries (2017-2019)
Figure Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2019)
Figure China Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure China Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Japan Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Korea Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure India Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure South America Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2019)
Figure South America Latent Tuberculosis Infection (LTBI) Testing by Countries (2017-2019)
Figure South America Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Brazil Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Argentina Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Columbia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Rest of South America Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing by Countries (2017-2019)
Figure Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Egypt Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Nigeria Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure South Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Turkey Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Table QIAGEN Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table BioMeriux S.A. Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table F. Hoffmann La-Roche Ltd. Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table BD Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table ARKRAY, Inc. Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table Abbott Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table Serum Institute of India Pvt. Ltd Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table Oxford Immunotec Ltd Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Table Lionex GmbH Latent Tuberculosis Infection (LTBI) Testing Financial Overview
Figure Global Latent Tuberculosis Infection (LTBI) Testing Revenue (Millions USD) and Growth Rate (2019-2027)
Table Latent Tuberculosis Infection (LTBI) Testing Market Forecast by Regions (2019-2027)
Figure North America Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure United States Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Canada Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Mexico Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Europe Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Germany Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure France Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure UK Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Russia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Italy Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Rest of Europe Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure China Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Japan Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Korea Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure India Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Southeast Asia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure South America Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Brazil Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Argentina Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Columbia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Rest of South America Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Saudi Arabia Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure United Arab Emirates Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Egypt Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Nigeria Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure South Africa Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Turkey Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Latent Tuberculosis Infection (LTBI) Testing Market Forecast (2019-2027)
Figure Global Latent Tuberculosis Infection (LTBI) Testing Forecast by Type (2019-2027)
Figure Global Latent Tuberculosis Infection (LTBI) Testing Market Share Forecast by Type (2019-2027)
Figure Global Latent Tuberculosis Infection (LTBI) Testing Forecast by Type (2019-2027)
Figure Global Latent Tuberculosis Infection (LTBI) Testing Forecast by Applications (2019-2027)
Figure Global Latent Tuberculosis Infection (LTBI) Testing Market Share Forecast by Applications (2019-2027)
Figure Global Latent Tuberculosis Infection (LTBI) Testing Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|